All Relations between Neurodegenerative Diseases and dopaminergic

Publication Sentence Publish Date Extraction Date Species
Diana A Quintero-Espinosa, Marlene Jimenez-Del-Rio, Carlos Velez-Pard. LRRK2 Kinase Inhibitor PF-06447475 Protects Drosophila melanogaster against Paraquat-Induced Locomotor Impairment, Life Span Reduction, and Oxidative Stress. Neurochemical research. 2024-06-07. PMID:38847910. parkinson's disease (pd) is a complex multifactorial progressive neurodegenerative disease characterized by locomotor alteration due to the specific deterioration of dopaminergic (daergic) neurons in the substantia nigra pars compacta (snpc). 2024-06-07 2024-06-10 human
Fernanda Vidal Carvalho, Harold E Landis, Bruk Getachew, Victor Diogenes Amaral Silva, Paulo R Ribeiro, Michael Aschner, Yousef Tizab. Iron toxicity, ferroptosis and microbiota in Parkinson's disease: Implications for novel targets. Advances in neurotoxicology. vol 11. 2024-05-23. PMID:38770370. parkinson's disease (pd) is a progressive neurodegenerative disease characterized by loss of dopaminergic neurons in substantia nigra pars compacta (snpc). 2024-05-23 2024-05-27 Not clear
Xiang Tao, Wenfei Zhang, Chen Chen, Yang Tao, Yun Tao, Zhibiao Chen, Ge Zhan. miR-101a-3p/ROCK2 axis regulates neuronal injury in Parkinson's disease models. Aging. vol 16. 2024-05-22. PMID:38775730. parkinson's disease (pd) is a neurodegenerative disease characterized by the loss of dopaminergic neurons in substantia nigra pars compacta (snpc). 2024-05-22 2024-05-27 Not clear
Sen-Miao Li, Dian-Dian Wang, Dan-Hua Liu, Xiao-Yan Meng, Zhizhong Wang, Xitong Guo, Qian Liu, Pei-Pei Liu, Shu-Ang Li, Songwei Wang, Run-Zhou Yang, Yuming Xu, Longde Wang, Jian-Sheng Kan. Neurotransmitter accumulation and Parkinson's disease-like phenotype caused by anion channelrhodopsin opto-controlled astrocytic mitochondrial depolarization in substantia nigra pars compacta. MedComm. vol 5. issue 6. 2024-05-18. PMID:38756440. parkinson's disease (pd) is a mitochondria-related neurodegenerative disease characterized by locomotor deficits and loss of dopaminergic (da) neurons in the 2024-05-18 2024-05-27 Not clear
Xia-Yin Cao, Yi Liu, Jia-Shuo Kan, Xin-Xing Huang, Piniel Alphayo Kambey, Can-Tang Zhang, Jin Ga. Microglial SIX2 suppresses lipopolysaccharide (LPS)-induced neuroinflammation by up-regulating FXYD2 expression. Brain research bulletin. 2024-04-30. PMID:38688414. parkinson's disease (pd) is a severe neurodegenerative disease associated with the loss of dopaminergic (da) neurons in the substantia nigra (sn). 2024-04-30 2024-05-03 Not clear
Camila de Oliveira Vian, Marcelo Augusto Germani Marinho, Magno da Silva Marques, Mariana Appel Hort, Marcos Freitas Cordeiro, Ana Paula Hor. Effects of quercetin in preclinical models of Parkinson's disease: A systematic review. Basic & clinical pharmacology & toxicology. 2024-04-29. PMID:38682342. parkinson's disease (pd) is a neurodegenerative disease that affects dopaminergic neurons, thus impairing dopaminergic signalling. 2024-04-29 2024-05-01 mouse
Pengjun Wang, Chen Chen, Min Sha. Vincamine alleviates brain injury by attenuating neuroinflammation and oxidative damage in a mouse model of Parkinson's disease through the NF-κB and Nrf2/HO-1 signaling pathways. Journal of biochemical and molecular toxicology. vol 38. issue 5. 2024-04-17. PMID:38629493. parkinson's disease (pd) is a neurodegenerative disease featured by progressive loss of nigrostriatal dopaminergic neurons, the etiology of which is associated with the existence of neuroinflammatory response and oxidative stress. 2024-04-17 2024-04-19 mouse
Chih-Hsin Lin, Yih-Ru Wu, Chih-Ying Chao, Kuo-Hsuan Chang, Chiung-Mei Chen, Wan-Ling Chen, Pei-Ning Yang, Guey-Jen Lee-Che. Protective Effects of Coptis chinensis Rhizome Extract and Its Constituents (Berberine, Coptisine, and Palmatine) against α-Synuclein Neurotoxicity in Dopaminergic SH-SY5Y Cells. Biological & pharmaceutical bulletin. vol 47. issue 4. 2024-04-10. PMID:38599826. parkinson's disease (pd) is a common neurodegenerative disease with progressive loss of dopaminergic neurons in substantia nigra and the presence of α-synuclein-immunoreactive inclusions. 2024-04-10 2024-04-13 human
Seyed Zanyar Athari, Fereshteh Farajdokht, Rana Keyhanmanesh, Gisou Mohadde. AMPK Signaling Pathway as a Potential Therapeutic Target for Parkinson's Disease. Advanced pharmaceutical bulletin. vol 14. issue 1. 2024-04-08. PMID:38585465. parkinson's disease (pd) is the second most common neurodegenerative disease caused by the loss of dopaminergic neurons. 2024-04-08 2024-04-10 Not clear
Rou Gu, Jianyu Pan, Maher Un Nisa Awan, Xiaowei Sun, Fang Yan, Liping Bai, Jie Ba. The major histocompatibility complex participates in Parkinson's disease. Pharmacological research. 2024-04-07. PMID:38583689. parkinson's disease (pd) is a common neurodegenerative disease characterized by progressive loss of dopaminergic neurons in the substantia nigra and the aggregation of alpha-synuclein (α-syn). 2024-04-07 2024-04-10 Not clear
Hyeyoon Eo, Shin-Hye Yu, Yujin Choi, Yujin Kim, Young Cheol Kang, Hanbyeol Lee, Jin Hee Kim, Kyuboem Han, Hong Kyu Lee, Mi-Yoon Chang, Myung Sook Oh, Chun-Hyung Ki. Mitochondrial transplantation exhibits neuroprotective effects and improves behavioral deficits in an animal model of Parkinson's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2024-04-05. PMID:38580511. among the diseases related to mitochondrial dysfunction, parkinson's disease (pd) is the second most common neurodegenerative disease and is characterized by dopaminergic neuronal loss and neuroinflammation. 2024-04-05 2024-04-10 mouse
Jean-Louis A Parmasad, Konrad M Ricke, Benjamin Nguyen, Morgan G Stykel, Brodie Buchner-Duby, Amanda Bruce, Haley M Geertsma, Eric Lian, Nathalie A Lengacher, Steve M Callaghan, Alvin Joselin, Julianna J Tomlinson, Michael G Schlossmacher, William L Stanford, Jiyan Ma, Patrik Brundin, Scott D Ryan, Maxime W C Rousseau. Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy. Cell death & disease. vol 15. issue 4. 2024-04-04. PMID:38575601. parkinson's disease (pd) is a debilitating neurodegenerative disease characterized by the loss of midbrain dopaminergic neurons (dans) and the abnormal accumulation of α-synuclein (α-syn) protein. 2024-04-04 2024-04-07 mouse
Jindong Zhao, Ji Wang, Kunying Zhao, Yuxiao Zhang, Weiyan H. Protopanaxadiols Eliminate Behavioral Impairments and Mitochondrial Dysfunction in Parkinson's Disease Mice Model. Neurochemical research. 2024-03-29. PMID:38551796. currently, there are no effective therapies to cure parkinson's disease (pd), which is the second most common neurodegenerative disease primarily characterized by motor dysfunction and degeneration of dopaminergic neurons in the substantia nigra pars compacta (snc). 2024-03-29 2024-04-01 mouse
Bandar Alharbi, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Engy Elekhnawy, Hind Alharbi, Athanasios Alexiou, Marios Papadakis, Gaber El-Saber Batih. Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit. European journal of medical research. vol 29. issue 1. 2024-03-28. PMID:38539252. parkinson's disease (pd) is a progressive neurodegenerative disease as a result of the degeneration of dopaminergic neurons in the substantia nigra pars compacta (snpc). 2024-03-28 2024-03-30 Not clear
Jianing Shen, Junhua Xie, Liyuan Ye, Jian Mao, Shihao Sun, Weiwei Chen, Sijia Wei, Sisi Ruan, Linhai Wang, Hangcui Hu, Jingjing Wei, Yao Zheng, Zhouyan Xi, Ke Wang, Yan X. Neuroprotective effect of green tea extract (-)-epigallocatechin-3-gallate in a preformed fibril-induced mouse model of Parkinson's disease. Neuroreport. 2024-03-25. PMID:38526966. parkinson's disease (pd) is the second most common neurodegenerative disease characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra (sn). 2024-03-25 2024-03-28 mouse
Haley M Geertsma, Zoe A Fisk, Lillian Sauline, Alice Prigent, Kevin Kurgat, Steve M Callaghan, Michael X Henderson, Maxime W C Rousseau. A topographical atlas of α-synuclein dosage and cell type-specific expression in adult mouse brain and peripheral organs. NPJ Parkinson's disease. vol 10. issue 1. 2024-03-20. PMID:38504090. parkinson's disease (pd) is the second most common neurodegenerative disease worldwide and presents pathologically with lewy pathology and dopaminergic neurodegeneration. 2024-03-20 2024-03-23 mouse
Kanika Bhardwaj, Neelu Kanwar Rajawat, Nupur Mathu. Development of Alpha-Synuclein protein model against therapeutic aspects of Parkinson's disease. Indian journal of pharmacology. vol 56. issue 1. 2024-03-08. PMID:38454587. journal/ijpha/04.03/01363791-202456010-00007/figure1/v/2024-03-07t095025z/r/image-tiff parkinson's disease (pd) is the most common neurodegenerative disease caused by the steady depletion of dopamine in the striatum due to the loss of dopaminergic neurons. 2024-03-08 2024-03-10 Not clear
Kandatege Wimalasena, Oluwatosin Adetuyi, Maya Eldan. Metabolic energy decline coupled dysregulation of catecholamine metabolism in physiologically highly active neurons: implications for selective neuronal death in Parkinson's disease. Frontiers in aging neuroscience. vol 16. 2024-03-07. PMID:38450382. parkinson's disease (pd) is an age-related irreversible neurodegenerative disease which is characterized as a progressively worsening involuntary movement disorder caused by the loss of dopaminergic (da) neurons in substantia nigra pars compacta (snpc). 2024-03-07 2024-03-09 Not clear
Lingling Zhang, Hao Yan. Research progress of neural stem cells as a source of dopaminergic neurons for cell therapy in Parkinson's disease. Molecular biology reports. vol 51. issue 1. 2024-02-24. PMID:38400887. parkinson's disease (pd) is a neurodegenerative disease, the most characteristic pathological feature is the progressive loss of dopaminergic (da) neurons in the substantia nigra pars compactus (snpc) of the mesencephalon, along with reduced dopamine content in the striatum. 2024-02-24 2024-02-27 Not clear
Areej Turkistani, Hayder M Al-Kuraishy, Ali I Al-Gareeb, Ali K Albuhadily, Athanasios Alexiou, Marios Papadakis, Mohamed M Elfiky, Hebatallah M Saad, Gaber El-Saber Batih. Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue. Molecular neurobiology. 2024-02-17. PMID:38367137. parkinson's disease (pd) is a progressive neurodegenerative disease of the brain due to degeneration of dopaminergic neurons in the substantia nigra (sn). 2024-02-17 2024-02-20 Not clear